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CLINICAL TRIALS AND OBSERVATIONS
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X-linked lymphoproliferative disease
(XLP1) is a rare immunodeficiency charac-
terized by severe immune dysregulation
and caused by mutations in the SH2D1A/
SAP gene. Clinical manifestations are
varied and include hemophagocytic lym-
phohistiocytosis (HLH), lymphoma and
dysgammaglobulinemia, often triggered
by Epstein-Barr virus infection. Historical
data published before improved treat-
ment regimens shows very poor out-
come. We describe a large cohort of 91 ge-
netically defined XLP1 patients collected
from centers worldwide and report char-
acteristics and outcome data for 43 pa-
tients receiving hematopoietic stem cell
transplant (HSCT) and 48 untransplanted
patients. The advent of better treatment
strategies for HLH and malignancy has
greatly reduced mortality for these pa-
tients, but HLH still remains the most
severe feature of XLP1. Survival after
allogeneic HSCT is 81.4% with good im-
mune reconstitution in the large majority
of patients and little evidence of posttrans-
plant lymphoproliferative disease. How-
ever, survival falls to 50% in patients with
HLH as a feature of disease. Untrans-
planted patients have an overall survival
of 62.5% with the majority on immuno-
globulin replacement therapy, but the out-
come for those untransplanted after HLH
is extremely poor (18.8%). HSCT should
be undertaken in all patients with HLH,
because outcome without transplant is
extremely poor. The outcome of HSCT for
other manifestations of XLP1 is very good,
and if HSCT is not undertaken immedi-
ately, patients must be monitored closely
for evidence of disease progression.
(Blood. 2011;117(1):53-62)
Introduction
X-linked lymphoproliferative disease (XLP) is a rare primary
immunodeficiency first described in 1975 by Purtilo1 and character-
ized by severe immune dysregulation often after viral infection
(typically with Epstein-Barr virus [EBV]). Since XLP was first
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described, our understanding of the molecular and cellular patho-
genesis of the disease has greatly improved. However, clinically, it
is still difficult to determine optimal management and prognosis for
patients due to the variability of clinical presentation, lack of
genotype-phenotype correlation, and rarity of the disease. Purtilo
established an XLP registry in 1980, and by 1995 more than
270 boys had been identified in 80 kindreds.2 To date this registry
has provided the only data on clinical phenotype and prognosis for
this patient group. Overall mortality in this group was 75%, with
70% of boys succumbing before 10 years of age. However, current
outcomes for XLP may be very different due to the availability of
unambiguous molecular diagnosis, improved viral monitoring, and
the improvement in treatment regimens for disease manifestations.
XLP affects 1 to 3 million boys,3,4 and most commonly presents
in childhood or early adolescence. Presentation may be acute in the
case of fulminant infectious mononucleosis (FIM)/hemophago-
cytic lymphohistiocytosis (HLH) or lymphoma or less aggressive
with dysgammaglobulinemia or recurrent infections. Patients often
manifest more than one phenotype and may progress from one
phenotype to another, for example presenting with hypogam-
maglobulinemia and progressing to lymphoma, and different
clinical features are often present in families highlighting the lack
of genotype-phenotype correlation. Other rare but well-described
presenting features include aplastic anemia, vasculitis, and chronic
gastritis.2,5-8 It is now known that the clinical syndrome of XLP
arises from 2 different genetic defects in SH2D1A (XLP1, by far
the most common and the focus of this report) and the BIRC/XIAP
gene (XLP2). The gene responsible for XLP1 is the SH2D1A gene
found on the X chromosome at position Xq25,9-11 which encodes
the cytoplasmic protein SAP (signaling lymphocyte activation
molecule or SLAM-associated protein). SAP is a key regulator of
normal immune function in T cells,12-14 natural killer (NK)
cells,15-18 NKT cells,19,20 and possibly B cells,21 and defects in
this protein lead to the varied immune defects described in
XLP1 patients.20,22 Humoral defects seen in this disease are thought
to arise from impaired CD4 T-cell interaction with B cells and not
an intrinsic B-cell deficit.23
Although it has always been presumed that EBV infection
plays a crucial role in the development of clinical features in
XLP1 patients, it is now clear that a proportion of boys are EBV
negative at presentation and remain so. Indeed, 10% of patients
have immunological abnormalities before any evidence of EBV
exposure.4,24 XLP1 is therefore a disorder of immune dysregulation
rather than a disorder specifically associated with EBV infection.
Before 1994, acute management of FIM and HLH included
antiviral medications, high-dose intravenous immunoglobulin (Ig),
immunosuppressants, and other immune modulators such as inter-
feron-. These treatments proved disappointing25 and the XLP
registry data showed a survival of only 4% for boys presenting with
these manifestations. Improved chemotherapy regimes for lym-
phoma and immunosuppressive protocols to treat HLH (including
rituximab) may reduce the mortality rate for XLP1 patients and
allow stabilization before hematopoietic stem cell transplant
(HSCT).26 Our report provides valuable outcome data collected
since the introduction of current HLH treatment protocols, focusing
on XLP1 patients with mutations in the SH2D1A gene.
Allogeneic HSCT remains the only curative option for XLP1 at
present although large scale outcome studies are not available.
Recently, Lankester et al reviewed 14 cases in the literature who
had undergone HSCT and found an overall survival of 71% (10/14)
with little evidence of EBV reactivation and posttransplant lym-
phoproliferative disease.27 We describe here outcome data for a
much larger cohort of patients transplanted since 1997.
There is no consensus on whether clinically stable XLP1 patients
should undergo HSCT as the natural history of the disease is so variable,
even within the same family. Treatment and management of the disease
is severely hampered by the lack of data of a large cohort of patients and
previously published outcome data are based on historical data,
which may represent patients with conditions other than XLP1 as
inclusion was based on clinical and not genetic diagnosis. Also,
little recent data exist for patients who remain untransplanted. Hence, we
describe a large cohort of genetically defined XLP1 patients collected
from centers worldwide. The data presented will allow for better
counseling of affected families regarding prognosis and management
options, particularly in relation to timing of transplant.
Methods
Data collection
Questionnaires regarding patient demographics, transplant characteristics,
and outcome were sent to centers worldwide identified through the
European Society for Immunodeficiencies/European Bone Marrow Trans-
plantation Registry, published case reports or centers known to perform
pediatric HSCT. Retrospective analysis was performed using data collected
for 91 patients from 32 centers worldwide. The number of cases from each
center varied between 1 and 27 but was on average 1-2 cases. Patients
included in this study were born between 1941 and 2005; 63 were born in or
after 1990 (24 untransplanted patients and 39 transplanted patients). Only
patients with a confirmed mutation in the SH2D1A gene were included in
this series. Patients with mutations in other XLP-associated genes such as
XIAP/BIRC-4 were excluded, as were patients with abnormal SAP
expression but no confirmed mutation in SH2D1A. EBV status was
determined by polymerase chain reaction to avoid variable serology results
in XLP1 patients and especially in those with dysgammaglobulinemia.
Questionnaires offered reporting of FIM and HLH separately; thus, some
centers with experience in this area reported patient data accordingly, and it
is presented as such.
Data in various forms from 11 patients have been previously pub-
lished5,27-32 but standardized information was recollected in this study and
added to the series.
Management of HLH and lymphoma
Patients who presented with HLH were managed predominantly in
accordance with HLH 94 or HLH 2004 protocols. Additional or alternative
treatment included antiviral therapy (aciclovir, ganciclovir, or foscarnet,
n  6), high-dose intravenous immunoglobulin (n 9), immunosuppres-
sion (steroids, cyclosporine, and etoposide, n 12), or anti-CD20 antibody
(rituximab, n 10). Intrathecal therapy was used where central nervous
system involvement was suspected. Ten patients who proceeded to trans-
plant received rituximab therapy before transplant, either as treatment for
HLH or during conditioning.
Regimes for the treatment of lymphoma varied in line with appropriate
national guidelines (eg, COPAD [cyclophosphamide, vincristine, predni-
sone, and doxorubicin]) study, Berlin-Frankfurt-Munster Group, Associazi-
one Italiana Ematologia Oncologia Pediatrica, or United Kingdom Chil-
dren’s Cancer Study Group guidelines) and only occasionally involved
surgical management.
Statistical analysis
Kaplan-Meier curves were used to analyze survival figures. The log rank
test (Mantel-Cox) and Gehan-Breslow-Wilcoxon tests were used to com-
pare survival between different groups. Statistical analysis including hazard
ratio calculation was performed using GraphPad Prism Version 5.00 for
Windows.
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Results
Data from 91 patients (64 pedigrees) in 32 centers worldwide were
included in this report. The overall survival of XLP1 patients was
71.4% (65/91), and patients displayed a heterogeneous clinical
phenotype. Due to the heterogeneity of the group, data were
analyzed according to presentation with HLH, EBV status, and
whether patients had received HSCT, allowing characterization of
outcome after transplant.
Spectrum of XLP1 mutations
In keeping with previous publications, no genotype/phenotype
correlation was evident, and the most frequently reported mutation
involved the arginine residue at position 55 (exon 2) found in
11 patients from 9 different families. Detailed genetic information
was available for 62 patients (50 pedigrees; supplemental Table 1,
available on the Blood Web site; see the Supplemental Materials
link at the top of the online article). Exon 2 had the most mutations
with missense mutations accounting for the majority but nonsense,
frameshift, and splice site mutations were also reported. Large gene
deletions (up to 11 Mb) including those involving the whole gene
were identified in 5 families. Three of these larger deletions were
associated with gastrointestinal symptoms of colitis and gastritis.
Such symptoms were not found in patients with other mutations
apart from a patient with diarrhea as a feature (missense mutation
exon 1, 62 T C). In a further 29 patients, detailed genetic data
were not supplied but a SAP/SH2D1A gene defect was confirmed
by the documenting center.
Clinical manifestations of XLP1
Table 1 shows the presenting features of disease as well as features
of disease manifesting throughout the course of the condition. HLH
remained the most common presenting feature (39.6%), although
dysgammaglobulinemia was the manifestation seen most com-
monly in patients during the course of the illness.
Although clinical features have remained similar to previously
published data,2 the survival associated with XLP1 is 71.4%, which
is significantly improved over historical survival of 25%. The
survival associated with different phenotypes has also changed
significantly with mortality associated with HLH decreased from
96% to 65%, lymphoproliferative disease from 35% to 8%, and
dysgammaglobulinemia from 55% to 5%.
Twenty-two patients suffered from malignant lymphoprolifera-
tive disease, with eighteen patients (81.8%) diagnosed with B-cell
non-Hodgkin lymphoma mainly of the abdomen and cervical
region. In 5 patients the disease was recurrent, with 1 patient
experiencing a cerebral tumor. Only 1 patient was reported with
cerebral T-cell lymphoma. Data on tumor histology is lacking in
3 patients.
Immunological abnormalities at diagnosis
Details of immune function were available for 57 patients, although
in some cases, data were only available after the onset of disease
manifestations that may have influenced immunoglobulin and
lymphocyte subset levels. Immunoglobulin levels were recorded
in 49 patients, and 32 of these showed varying degrees of
abnormal immunoglobulin levels. Twelve children presented with
neutropenia. Lymphocyte subset data were available for 47 pa-
tients; 19 showed a reduced percentage of B cells, 26 showed low
NK cell numbers, and 12 had a reversed CD4:CD8 ratio.
Presentation with HLH
The mortality for patients presenting with HLH was 65.6%, with a
median age at presentation of 3 years 2 months (range 8 months to
9 years). Of the 32 patients with HLH, 16 underwent transplant, of
whom 8 survived (50%; Figure 1). Of those who did not receive a
transplant, only 3 survived (18.8%), confirming previous reports
that the prognosis for patients with HLH associated with a genetic
defect is extremely poor and that HSCT is necessary.
EBV status
EBV status was documented in 79 patients showing that 51 (64.6%)
were EBV positive at presentation or diagnosis (Table 2 and supplemen-
tal Figure 1). The median age of presentation in this group was
4 years (range 8 months to 40 years), and the overall mortality was
35.2% (18/51). There was no significant difference in mortality between
patients with (35.2%) and without (28.6%) documented EBV infection.
Table 1. Presenting symptoms and features of XLP1 patients with
associated mortality
Incidence Mortality
Presenting symptom
HLH 31.9% 65.5%
FIM 7.7% 14.3%
Lymphoma 14.3% 7.7%
Dysgammaglobulinemia 22% 5%
Family history of
XLP1 alone
16.5% 20%
Other 7.7% 14.3%
Features occurring at any time
HLH 35.2% 65.6%
FIM 9.9% 22.2%
Lymphoma 24.2% 9%
Dysgammaglobulinemia 50.5% 13%
Other 15.4% 28.6%
Figure 1. Outcome of patients with HLH during course of disease. Survival of
patients who present with HLH—patients who remain untransplanted have a poor
survival outcome with only 18.8% survival. By contrast the survival of those who
undergo transplant is higher at 50%.
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HLH/FIM was the most common feature in this group being seen in
35 patients (68.6%), with lymphoma present in 10 patients (19.6%), and
dysgammaglobulinemia in 19 (37.2%). Nine EBV-positive patients had
a family history of XLP1, and two others had a family history suggestive
of an X-linked immunodeficiency. Of the 18 EBV-positive patients who
died, the majority (14/18) died within 2 months of presentation due to
disease progression. Three died in the early posttransplant period of
infective complications and disease progression, and 1 died during
treatment for lymphoma.
Twenty-eight patients were EBV negative at presentation or
diagnosis. The median age of presentation for this group was
3 years (range birth to 31 years). Family history of XLP1 was the
presenting feature for 12 patients, and a further 7 patients described
a family history suggestive of an X-linked immunodeficiency or
lymphoma. There was a higher rate of dysgammaglobulinemia
(51.8%) in this group. Lymphoma was present in 7 patients. Fewer
EBV negative patients presented with HLH/FIM, and this may
suggest that at least for this manifestation a viral trigger is
important. Information was sought on other viral infectious agents
including cytomegalovirus and adenovirus, but data were not
available for most patients. Other clinical features included aplastic
anemia in 3 patients and vasculitis in 2 patients. The mortality for
this EBV negative group was 28.6% (8/28); 3 patients died shortly
after presentation before HSCT with central nervous system
vasculitis (2) and HLH with enterococcal sepsis (1). One patient
died 11 years after presentation following a complex course, and
a further 4 patients died in the early posttransplant period (de-
scribed in Table 5).
HSCT for XLP1
HSCT was undertaken in 22 centers (range of patients/center: 1-7)
between 1997 and 2009 (Table 3). Forty-six transplants were
performed on 43 patients, and the median age at transplant was
6.25 years (range 8 months to 19 years); 1 patient who had
undergone a haploidentical transplant received a CD34 selected
boost 1 year after initial transplant. One patient received an
allogeneic HSCT to treat lymphoma before a diagnosis of XLP1
was established. Most patients received bone marrow or peripheral
blood stem cells, and only 2 patients received umbilical cord
HSCT. Donor grafts were from human leukocyte antigen-matched
family donors in 14 cases, mismatched family donors or matched
unrelated grafts in 28 cases, and haploidentical donors in 4 cases.
Half of the transplant procedures (23/46) were performed using
myeloablative conditioning regimes including combinations of
Figure 2. Survival in XLP1 related to different variables. (A) Overall survival of transplanted versus untransplanted patients. In the transplanted group this represents time
from presentation and not transplant. (B) Survival according to donor source. (C) Survival after HSCT with relation to presence of HLH before transplant. (D) Survival according
to age at transplant.
Table 2. Characteristics of EBV-positive and EBV-negative
XLP1 patients
EBV positive
(64.6%, n  51)
EBV negative
(35.4%, n  28)
Median age at presentation 4 y (8 mo-40 y) 3 y (0-31 y)
Family history of XLP1 17.6% 42.9%
HLH 51% 21.4%
FIM 17.6%
Lymphoma 19.6% 25%
Dysgammaglobulinemia 37.2% 51.8%
Mortality 35.2% 28.6%
Median age at death 3 y 6 mo (14 mo-21 y) 5 y 11 mo (20 mo-31 y)
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busulfan 12-20 mg/kg, cyclophosphamide 50-200 mg/kg, and total
body irradiation 5-12 Gy. The other half of procedures used
nonmyeloablative conditioning regimes consisting of fludarabine
(30 mg/kg), melphalan (70-140 mg/kg), busulphan (4-12 mg/kg),
or total body irradiation (3-5 Gy). Twenty-six patients received
additional serotherapy with alemtuzumab, anti-thymocyte globu-
lin, anti-CD3 antibody, and anti-CD20 antibody (rituximab). Graft-
versus-host disease (GVHD) prophylaxis regimes differed between
centers, but mostly involved combinations of cyclosporin with
methotrexate, mycophenolate mofetil, steroids, and tacrolimus.
T-cell depletion of the graft was used in 1 case.
Outcome for XLP1 patients who received allogeneic HSCT
was good with 81.4% surviving the procedure (35/43) with a median
follow up of 52 months. The majority of these patients (28/35 survivors)
required no ongoing immunoglobulin replacement therapy. Tables 3 and
4 highlight details of transplanted patients, and Figure 2 describes
survival according to several factors.
Sixteen patients were diagnosed with HLH before transplant
and 12 patients had some form of lymphoproliferative disease
(lymphoma). Only 51.2% of the cohort had documented evidence
of EBV infection (by polymerase chain reaction) with survival
rates in EBV patients similar to those without EBV infection
(75% vs 80%). Most patients experienced some delay from first
symptoms to diagnosis (average delay 2 years 7 months) but once a
diagnosis of XLP1 was established time to transplant was generally
less than 1 year. Median age at transplant was 6.25 years with a
range of 8 months to 19 years.
Univariate analysis was performed to identify the major risk
factors for survival after HSCT. The most important risk factor was
prior HLH, which significantly decreased the survival outcome to
50%. A previous diagnosis of lymphoma had a near significant
effect, but other variables were not shown to have a significant
effect including importantly, previous evidence of EBV infection,
the age at transplant, donor type, or the conditioning regime. It is
also important to note that only patients who had HLH at some
point before or during transplant died. Conversely, all patients
without HLH (n 27) survived the transplant procedure.
Half of the patients underwent a nonmyeloablative conditioning
regime before HSCT and this did not impact on survival (nonmyelo-
ablative vs myeloablative, 78.9% vs 82.9%) or long-term chimer-
ism. More than 90% of patients achieved full donor chimerism, and
Table 3. Characteristics of XLP1 patients receiving allogeneic HSCT
Percentage Number 1-y survival HR 95% CI P
XLP1 features
Previous HLH 37.2% 16/43 50% 23.93 5.31-108.0  .0001
Previous NHL 27.9% 12/43 74.2% 0.23 0.05-1.06 .06
Previous dysgammaglobulinemia 46.5% 20/43 80% 1.2 0.29-4.96 .77
EBV 51.2% 21/41 75% 1.37 0.36-5.3 .65
Age at HSCT Mean 7 y (8 mo to 19 y 7 mo)
0-2 y 9.3% 4/43 75% 5.75 0.11-302.1 .38
2-5 y 34.9% 15/43 78.6% 3.61 0.18-71.76 .40
5-15 y 48.8% 21/43 85.7% 3.16 0.11-90.83 .50
 15 y 7% 3/43 100%
Year of HSCT
 2000 7.0% 3/43 66.7%
2000-2005 37.2% 16/43 87.5%
2005-2009 55.8% 24/43 79.2%
Donor Type
MSD, MFD 30.4% 14/46 91.77%
MUD, mMFD, mMUD 60.9% 28/46 77.8% 0.42 0.08-2.07 .27
Haplo 8.7% 4/46 75% 0.24 0.01-6.58 .4
Source
Bone marrow 58.5% 24/41* 82.6%
Peripheral blood 36.6% 15/41* 92.9%
Umbilical cord 4.9% 2/41* 50%
Conditioning
MA 50% 23/46 82.9%
NMA 50% 23/46 78.9% 1.25 0.30-5.2 .77
Serotherapy 30.4% 14/46
GVHD 50% 19/38
Grade 1 18.4% 7/38
Grade 2-3 26.3% 10/38
Grade 4 5.3% 2/38
Chronic 5.3% 2/38
Chimerism
Full ( 98%) 92% 35/38 100%
Mixed 8% 3/38 88.8% 2.98 0.06-151.0 .59
Replacement IVIg 20% 7/35†
Alive 81.4% 35/43
Follow up 6 wk to 148 mo
*Data missing on 5 transplants, 1 died during conditioning.
†Three patients 1 year after transplant.
CI indicates confidence interval; HR, hazard ratio; MSD, matched sibling donor; MFD, matched family donor; MUD, matched unrelated donor; mMFD, mismatched family
donor; mMUD, mismatched unrelated donor; Haplo, haploidentical transplant; MA, myeloablative; and NMA, nonmyeloablative.
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those with a mixed or falling chimerism remained well with 1
patient still receiving replacement immunoglobulin.
Data were also collected on common posttransplant com-
plications such as GVHD, infectious complications and toxicity
attributable to chemotherapy. Half of the patients (50%) suffered
from some form of GVHD; the majority of cases were grade
1-3 affecting the skin, liver, and gut. Two patients suffered grade
4 disease (of skin and liver), and 1 of these children died. Only
2 patients went on to develop chronic GVHD (see Table 3). One
patient experienced both veno-occlusive disease and renal toxicity
due to conditioning (busulfan, cyclophosphamide, and antithymo-
cyte globulin), and this patient succumbed shortly after a haploiden-
tical transplant.
In 3 patients with mixed chimerism in peripheral blood
mononuclear cells, this remained stable in all but 1 patient, in
whom it fell from 92% to 5%. However, this patient remains well
3 years posttransplant and does not require replacement immuno-
globulin therapy. From this series, there is little evidence of viral
reactivation posttransplant. Thirty-five patients are alive with
5 suffering some long-term effects including EBV viremia (man-
aged with rituximab), bronchiectasis, autoimmune disease, chronic
psoriasis, and neutropenia.
Eight patients did not survive after HSCT (see Table 5). Seven
patients who died presented with HLH before HSCT (4/7 EBV)
compared with 8 of 35 survivors, but HLH was a feature of disease
in all 8 nonsurvivors. The majority of nonsurvivors were 3 years
old (5/8), and conditioning regime did not appear to play a role as
5/8 patients received a full myeloablative regime. The main cause
of death in this group was sepsis, but disease progression accounted
for 2 deaths. The 2 children dying with disease progression went
into transplant with active disease; 1 died during conditioning and
the other 3 days after HSCT. One further patient died 3 weeks after
HSCT (7 months after presentation) from veno-occlusive disease
(VOD), multiorgan failure, and renal toxicity attributable to
chemotherapy. The remaining 5 patients died of sepsis (2 pseu-
domonal sepsis, 1 parainfluenza III infection, 1 with disseminated
adenoviral infection, and 1 with EBV and fungal infection) within
3 months of HSCT.
Untransplanted patients
Data were available for 48 patients who did not receive HSCT
(Table 6); 30 are alive, 4 of whom are actively awaiting transplant,
and 3 who refused HSCT. One patient had received an autologous
HSCT before diagnosis with XLP1, and this patient’s data were
Table 4. Details of XLP1 patients surviving allogeneic HSCT
Year of
HSCT EBV HLH
Age at
HSCT Donor
Conditioning/serotherapy/
graft manipulation
GVHD
prophylaxis GVHD Chimerism
Follow up
(mo) Ig
1997 NK 7 y MSD Cy, TBI MTX, CSA 1 S* 100% 148
1998 1 y MUD Bu, Cy, ATG MTX, CSA, P 1 S 100% 133
2000  4 y MUD Bu, Cy, Campath CSA 2 S 100% 102
2000  Yes 3 y mMUD Bu, Cy MTX, CSA 2 S, L 100% 107
2001 4 y MUD Flu, Melph, ATG, TBI MMF, CSA 100% 102
2001  10 y MSD Bu, Cy, VP-16 (NHL) MTX, CSA 2-3 GI 100% 99
2001 4 y MSD Bu, Cy CSA 2 S 100% 95
2002 13 y MSD Thio, Flu, ATG CSA 100% 88
2002  7 y MUD Bu, Cy, ATG MTX, CSA 1 S 100% 85
2002 3 y MUD Bu, Cy, ATG MTX, CSA 100% 84
2003 8 mo mMUD Flu, Melph, ATG, TBI TAC, MTX, P S 100% 79
2003 19 y MSD Thio, Flu, ATG CSA 100% 71
2003 11 y mMUD Flu, Melph, ATG MMF, CSA 100% 68
2004  5 y MSD Bu, Cy MTX, CSA 20% PBMC 66
2004  12 y mMFD Flu, Melph, Campath, 34 MMF, CSA 4 S, L* 100% 62 Y
2004  8 y mMUD Flu, Melph, Campath CSA 2-3 S, GI 100% 57
2005  Yes 2 y Haplo Bu, Cy, ATG, 34 CSA 100% 54 Y
2005 2 y Haplo Bu, Cy, ATG, 34, top up 1 year CSA 88% PBMC 97% M 50 Y
2005 12 y mMUD Flu, Melph, Campath, 34 MMF, CSA 3 S 100% 46
2005 18 y MUD NK NK 46 NK
2006 5 y MSD Bu, Cy CSA 1 G, 3 S 100% 42
2006 NK 2 y MUD Bu, Flu, Campath MTX 100% 42
2006  7 y Haplo Flu, Melph, Thio, OKT3, ATG 100%, 75% CD3 39
2006  Yes 1 y MUD Flu, Melph, Ritux CSA 1 S 5% 38
2006  11 y MSD Bu, Cy, ATG MTX, CSA 100% 35
2006 4 y MUD Bu, Cy, Campath MMF, CSA 1 S 100% 33
2007  Yes 6 y MSD Bu, Cy MTX, CSA 99% 30
2007  Yes 7 y MSD Bu, Cy CSA 3 S, L, GI 100% 29
2007 NK 7 y MUD Flu, Melph, TBI TAC, MTX 98% 27
2007 7 y MSD/mMUD Bu, Cy CSA 2 S, GI 100% 26
2008 17 y MFD Flu, Melp, Campath MMF, CSA 100% 13
2008 Yes 3 y MUD Bu, Flu TAC, MTX 100% 9 Y
2009  7 y MUD Bu, Cy 100% 6 Y
2009  Yes 6 y mMUD Flu, Melph, Campath CSA, MMF 1 S 100% 5 Y
2009  Yes 3 y MUD Thio, Cy, ATG CSA, P 100% 4 Y
*Chronic GVHD.
PBMC indicates peripheral blood mononuclear cell; Flu, fludarabine; Melph, melphalan; 34, CD34 stem cell infusion; Bu, busulfan; Cy, cyclophosphamide;
Thio, thiotepa; TBI, total body irradiation; CSA, cyclosporin A; MMF, mycophenalate mofetil; MTX, methotrexate; P, prednisolone; TAC, tacrolimus; S, skin; GI, gastrointestinal;
L, lung; and Ig, replacement immunoglobulin.
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analyzed as though untransplanted. Less detailed information was
available for this set of patients compared with those receiving
HSCT. This may be because some patients died before EBV status
and immune function could be established and any first symptoms
may not have been recognized as a manifestation of XLP1. From
data available, median age at presentation was 5 years, and delay in
diagnosis ranged from a few weeks to 32 years.
Presentation was highly variable but as expected included
HLH/FIM, dysgammaglobulinemia, and recurrent infection. More
unusual presentations included 1 patient with central nervous
system vasculitis, intracranial hemorrhage and myocardial fibrosis,
and peripheral eosinophilia. The course of XLP1, both temporal
and clinical, was extremely variable without any apparent correla-
tion to family history or genetic mutation.
Table 5. Details of XLP1 patients not surviving allogeneic HSCT
EBV HLH
Age at
HSCT, y Year of HSCT Donor
Conditioning/serotherapy/
graft manipulation
GVHD
prophylaxis GVHD Chimerism Cause of death
 Yes 2 2005 MMFD Flu, TBI N/A Died during conditioning
6 wk from presentation
 Yes 3 2003 MUD Bu, Flu, Campath, Rituximab CSA Died 3 d after HSCT disease
progression
Yes 6 2005 MMFD Bu, TBI MMF. MTX, P Died 14 d after HSCT MDR
pseudomonal sepsis
 Yes 3 2009 Haplo Bu, Cy, ATG TCD Died 3 wk after HSCT VOD,
MOF, renal toxicity
 (after HSCT) Yes 5 2008 mMUD (cord plus
PBSC 4 months
later)
Bu, Flu, ATG then Flu, TBI TAC, P 100% Died 2 mo after second
HSCT EBV, fungal, and
?PCP sepsis
Yes 3 1998 MSD 2 Flu, Melph CSA, P 100% Died 3 mo after HSCT
Pseudomonas sepsis
 Yes 12 2003 MUD Bu, Cy, Flu, Campath 4 S 100% Died 3 mo after HSCT
disseminated adenovirus
Yes 1 2007 MUD Flu, Melph, ATG, 34 CSA 2-3 S, L 100% Died 3 mo after HSCT
paraflu III sepsis
PBSC indicates peripheral blood stem cell; Flu, fludarabine; Melph, melphalan; 34, CD34 stem cell infusion; Bu, busulphan; Cy, cyclophosphamide; Thio, thiotepa;
TBI, total body irradiation; CSA, cyclosporine A; MMF, mycophenalate mofetil; MTX, methotrexate; P, prednisolone; TAC, tacrolimus; TCD, T-cell depletion; S, skin; L, lung;
VOD, veno-occlusive disease; MOF, mullti-organ failure; MDR, multidrug resistant; and PCP, Pneumocystis jiroveci.
Table 6. Characteristics of XLP1 patients not receiving HSCT
Number
Age at first symptom 8 y 8 mo (6 mo-40 y)
Age at death 7.5 y (1-31 y)
Time from presentation to death 17.3 mo (1 NK) 9 d-18 y
Time from first symptom (in those patients alive) 12 y (1 NK) 1-39 y
Presenting symptom
HLH 31.3% 15/48
FIM 10.4% 5/48
Lymphoma 16.7% 8/48
Dysgammaglobulinemia 29.2% 14/48
Other 12.5% 6/48
Features
HLH 33.3% 16/48
FIM 12.5% 6/48
Lymphoma 20.1% 10/48
Dysgammaglobulinemia 56.3% 27/48
Gut 8.3% 4/48
Other 14.6% 7/48
EBV status
EBV 66.6% 32/48
EBV 14.6% 7/48
Unknown 18.8% 9/48
Mortality 37.5% 18/48 (4 EBV)
Associated with HLH 81.3% 13/16
Associated with FIM 33.3% 2/6
Associated with lymphoma 20% 2/10 1 had previous HLH and died during
chemotherapy; 1 had recurrent lymphoma
and many other problems
Immunoglobulin replacement
Yes 70% 21/30
No 23.3% 7/30
Unknown 6.7% 2/30
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As with transplanted patients the significant mortality associ-
ated with HLH is evident in untransplanted patients (81.3%).
Presentation or manifestation of HLH (n 15 and 16, respec-
tively) was associated with a rapid decline and death within
6 weeks, especially in patients less than 5 years of age. Of the
48 patients, 32 did not have manifestations of HLH, and in this
group 5 died, thereby giving a survival of 84.4% with a mean
follow-up in this group of 11.6 years. For those untransplanted
patients who survive, 70% received replacement immunoglobulin
therapy, with few suffering from long-term complications. Only
5 patients have recorded complications, including 1 with recurrent
infection, 1 with neutropenia, 1 with bronchiectasis, and 2 boys
with gastrointestinal disease and growth delay.
Supplemental Table 2 compares the demographics between
transplanted and untransplanted patients. No significant differences
were seen between the 2 populations other than mortality, which
was twice as high in the untransplanted cohort (P  .05). Age of
death was lower in transplanted patients and may reflect the more
severe course that may have led to the need for HSCT.
Discussion
This report summarizes data on 91 patients from 64 families
worldwide with a genetic diagnosis of XLP1 and provides informa-
tion on outcome with and without allogeneic HSCT using current
treatment protocols (summarized in Figure 3). This report is the
first large-scale analysis of XLP1 patients since the report by the
XLP1 registry in 1995 and has for the first time gathered patients
who have confirmed SAP/SH2D1A mutations. Therefore this
report represents a genetically homogeneous cohort and avoids
possible phenotypic variability through inclusion of other patients
with genetic defects such as XIAP/BIRC 4 mutations.
The clinical features of the disease are similar to those reported
by the XLP1 Registry, with HLH and FIM remaining the most
common and most lethal complication. With the advent of more
accessible genetic screening and mutation analysis confirming the
diagnosis, more patients have been diagnosed early on the basis of
family history and increased awareness of the disease has also led
to patients being diagnosed after presentation with immune dysregu-
lation and more unusual presenting features such as vasculitis.
A diagnosis of XLP1 is still a difficult one to make, and it is
possible that some patients mistakenly fall under the umbrella of
common variable immunodeficiency, although previous genetic
screening studies suggest that the incidence of XLP1 patients in
common variable immunodeficiency cohorts is low.33 It is also
possible that there are older individuals who present in adulthood
and have not been identified and included in this study, and this
may result in a bias in the method of data collection as the majority
of centers approached to contribute data were specialist pediatric
centers. For example, a recent case report describes a 41-year-old
man who presented with an EBV-induced central nervous system
B-cell lymphoma and absent B cells.34 The oldest surviving patient
from this cohort presented at the age of 7 years with recurrent
infections and hypogammaglobulinemia, but remains well without
transplant and is receiving replacement immunoglobulin therapy at
46 years of age.
The prognosis for XLP1 has greatly improved since 1995, when
Seemayer et al2 reported an overall survival of 25% survival with
71.4% of patients in this cohort alive at the time of data analysis.
Indeed, the mortality in untransplanted patients was lower than we
expected, with 62.5% surviving, including 3 boys who presented
with HLH, but the mortality in this group secondary to HLH
remains high at 81.3%. It is also interesting to note that a
considerable mortality of 28.6% is seen in EBV-negative patients
who do not receive HSCT and is related to HLH, sepsis, and
vasculitis, suggesting that underlying immunological abnormalities
in XLP1, and not only EBV-driven disease, can be fatal. Few complica-
tions from recurrent infection and immune dysregulation were reported,
suggesting that early diagnosis and good supportive care with replace-
ment immunoglobulin and prophylactic antibiotics can improve the
outcome for untransplanted patients. Although over 60% of patients
survive without HSCT, it will be important to follow patients carefully,
since there is the potential for more severe manifestations to arise, and
the options for transplant should be explored.
The mortality associated with the different clinical phenotypes
has changed over time, with an improved survival for both HLH
(34.5% vs 4%) and lymphoma (91% vs 35%).2 This most likely
reflects improved treatment strategies for both HLH (especially the
use of agreed protocols such as HLH 9435 and 200436) and malignancy.
Although these figures represent survival with either HLH or lymphoma
as features of XLP1 at any stage, they are very similar to the survival
seen if patients present with these features (44.5% and 92% for
HLH/FIM and lymphoma, respectively). A mortality of 13% in patients
who exhibit dysgammaglobulinemia is associated with HLH, infection,
vasculitis, and hemorrhage and highlights that although clinically this
phenotype may be milder, it is not an innocuous phenotype, and
progression to further fatal symptoms is not uncommon.
The outcome data following allogeneic HSCT from this report
is encouraging. The outcome data presented is the largest ever
Figure 3. Outcome of patients with SAP/SH2D1A mutations.
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gathered and shows that approximately 80% of patients survive the
procedure with complete cellular and humoral reconstitution in the
large majority of cases. In this series, there is little evidence of
problematic EBV reactivation adversely affecting transplant out-
come and no increased incidence of long-term complicating
features such as autoimmunity in comparison to transplant for other
conditions.37,38 Although donor chimerism in the majority of
patients was complete, even low level chimerism in 2 patients with
5% and 20% donor chimerism was associated with good immune
recovery. Conversely however, when the patients who required
ongoing immunoglobulin support are analyzed, all but 1 have
100% donor engraftment. Further detailed lineage-specific analysis
and study of T- and B-cell function in these patients is necessary to
determine why humoral function has not been established. The
availability of a fully matched donor is associated with an
improved survival outcome (approximately 92%), although with
the present low numbers this is not statistically significant.
Haploidentical grafts show a good outcome in this cohort, but the
numbers are extremely low (only 4 transplants performed), and
therefore this information needs to be interpreted with caution.
The most important factor affecting survival after transplant is a
manifestation of HLH, which significantly reduces survival to
50%. Indeed all 8 patients who died had a complication of HLH at
some point in their clinical course. This may reflect the effects of
HLH itself or HLH chemotherapy and immunosuppression on the
transplant process, including increased organ related toxicity and
increased susceptibility to pathogens. In comparison to data
reported on cohorts of patients undergoing transplant for HLH
associated with other gene defects (eg, perforin and munc 13-4)39-41
it appears that the outcome for HLH associated with XLP1 is worse
and may relate to the multiple immune deficits associated with SAP
deficiency. By contrast all XLP1 patients who had no HLH
manifestations (n 27) survived the HSCT procedure.
These data may now allow more informed recommendations to
be made regarding transplantation in XLP1. It is clear from this
report that HLH in XLP1 has a very poor prognosis if left
untransplanted. Therefore any individual with HLH as a manifesta-
tion of XLP1 should undergo allogeneic HSCT.
For patients who are newly diagnosed because of a family
history but with no clinical features or for those who present with
manifestations other than HLH/FIM, the decision to transplant a
relatively well child has been more challenging. An important
observation from this report is that all patients (n 27) who went
into transplant without prior HLH survived the procedure in
comparison to 84.4% survival for those who are untransplanted and
have not manifested with HLH. Since progression to HLH without
transplant may occur at a later stage, there is a strong argument to
transplant all individuals with a diagnosis of XLP1.
However, there is a counter argument to such a recommenda-
tion. As with other immunodeficiencies, the data collected and
presented here may not give a complete picture of the natural
course of XLP1 and is a historical cohort study conducted before
the advent of recent improved therapies. Further, milder patients
may also remain undiagnosed having been labeled with a diagnosis
of common variable immunodeficiency. It is also the case that HLH
is most often seen in younger patients (median age of presentation
3.2 years) and older individuals are less likely to manifest with
HLH. There may also be reluctance on the part of families and
physicians to undertake a transplant in a well child given that, even
in the best-case scenario, there will be a certain mortality associ-
ated with any allogeneic transplant procedure.
A more pragmatic recommendation would be to undertake
transplant in all patients presenting or manifesting with HLH.
Similarly for newly diagnosed or young children without any HLH,
if a well-matched donor is available, HSCT should be undertaken,
since a manifestation of HLH may be catastrophic or may severely
compromise transplant outcome. For older individuals, we would
still recommend that HSCT be undertaken, but this decision to
transplant should be based on available donor status, wellbeing of
the patient, and the attitude of family and physician to the risk of
transplant. If HSCT is not undertaken immediately, it is recom-
mended that a donor source is identified and that all patients
are followed very carefully in case of disease progression and
onset of other manifestations, at which point HSCT could be
performed rapidly.
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Errata
Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and
pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up. Blood.
2011;118(4):884-893.
On page 884 in the 28 July 2011 issue, there is an error in the affiliation of the first author (Cappellini). The word “Scientifico” is
misspelled. The affiliation should have read: “1Universita´ di Milano, Ca Granda Foundation Istituto di Ricovero e Cura a Carattere
Scientifico (IRCCS), Milan, Italy.” On pages 885, 887, 889, 891, and 893, there is an error in the running title of the article; the word
“EFFICIENCY” should be “EFFICACY.” The running title should have read: “DEFERASIROX 5-YEAR EFFICACY AND SAFETY.”
The errors were corrected in the online version, which now differs from the print version.
Booth C, Gilmour KC, Veys P, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A
deficiency: a multicenter study on the manifestations, management and outcome of the
disease. Blood. 2011;117(1):53-62.
On page 53 of the 6 January 2011 issue, the 17th author’s last name was misspelled Pachlopnick-Schmid. The correct name is Pachlopnik
Schmid. The error has been corrected in the online version, which now differs from the print version.
Gregori S, Tomasoni D, Pacciani V, et al. Differentiation of type 1 T regulatory cells (Tr1) by
tolerogenic DC-10 requires the IL-10–dependent ILT4/HLA-G pathway. Blood. 2010;116(6):935-
944.
On page 935 in the 12 August 2010 issue, one of the affiliations of the third author (Valentina Pacciani) is incorrect. The second affiliation
listed as “Department of Pediatrics, Universita` di Tor Vergata, Rome” should have been: “University Department of Pediatrics (DPUO),
Bambino Gesu` Children’s Hospital, Rome, Italy.” The correct byline and affiliations are shown. The error has been corrected in the online
version, which now differs from the print version.
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Gomes AL, Carvalho T, Serpa J, Torre C, Dias S. Hypercholesterolemia promotes bone marrow
cell mobilization by perturbing the SDF-1:CXCR4 axis. Blood. 2010;115(19):3886-3894.
On pages 3888, 3889, and 3892 in the 13 May 2010 issue, there are errors in the color of the bars in the plots of several figure panels. In
Figures 1C, 1D, 2B, 6B, and 6C, when parameters are compared between the 2 conditions, “Normal diet” on the left should be gray, and
“High-cholesterol diet” on the right should be black. The corrected Figures 1, 2, and 6 are shown.
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